A clinical trial has proposed that simultaneous elevation of serum bile acid and fibroblast growth factor 19 levels can be used as an indicator of early HCC screening in patients with type-2 diabetes mellitus (T2DM) [60]. The gene discussed is FGF19; the disease is type 2 diabetes mellitus.